Pliant Therapeutics Inc. (PLRX): Price and Financial Metrics
GET POWR RATINGS... FREE!
PLRX POWR Grades
- Sentiment is the dimension where PLRX ranks best; there it ranks ahead of 47.94% of US stocks.
- The strongest trend for PLRX is in Growth, which has been heading down over the past 177 days.
- PLRX's current lowest rank is in the Stability metric (where it is better than 9.8% of US stocks).
PLRX Stock Summary
- With a price/sales ratio of 181.91, PLIANT THERAPEUTICS INC has a higher such ratio than 98.16% of stocks in our set.
- With a year-over-year growth in debt of 141%, PLIANT THERAPEUTICS INC's debt growth rate surpasses 90.85% of about US stocks.
- In terms of volatility of its share price, PLRX is more volatile than 91.53% of stocks we're observing.
- Stocks that are quantitatively similar to PLRX, based on their financial statements, market capitalization, and price volatility, are AGIO, VXRT, TSVT, RXDX, and MRUS.
- Visit PLRX's SEC page to see the company's official filings. To visit the company's web site, go to pliantrx.com.
PLRX Valuation Summary
- In comparison to the median Healthcare stock, PLRX's price/sales ratio is 5407.32% higher, now standing at 112.9.
- Over the past 32 months, PLRX's price/sales ratio has gone up 100.1.
Below are key valuation metrics over time for PLRX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PLRX | 2023-01-20 | 112.9 | 3.3 | -9.7 | -9.5 |
| PLRX | 2023-01-19 | 110.0 | 3.2 | -9.5 | -9.2 |
| PLRX | 2023-01-18 | 111.9 | 3.2 | -9.6 | -9.4 |
| PLRX | 2023-01-17 | 115.1 | 3.3 | -9.9 | -9.7 |
| PLRX | 2023-01-13 | 117.6 | 3.4 | -10.1 | -9.9 |
| PLRX | 2023-01-12 | 118.6 | 3.4 | -10.2 | -10.0 |
PLRX's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PLRX has a Quality Grade of D, ranking ahead of 14.66% of graded US stocks.
- PLRX's asset turnover comes in at 0.047 -- ranking 325th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PLRX's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.047 | 1 | -0.360 |
| 2021-03-31 | 0.050 | 1 | -0.363 |
| 2020-12-31 | 0.149 | 1 | -0.245 |
PLRX Price Target
For more insight on analysts targets of PLRX, see our PLRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $51.33 | Average Broker Recommendation | 1.38 (Strong Buy) |
PLRX Stock Price Chart Interactive Chart >
PLRX Price/Volume Stats
| Current price | $34.87 | 52-week high | $36.64 |
| Prev. close | $36.26 | 52-week low | $3.96 |
| Day low | $34.87 | Volume | 1,039,100 |
| Day high | $36.64 | Avg. volume | 1,702,372 |
| 50-day MA | $20.98 | Dividend yield | N/A |
| 200-day MA | $16.65 | Market Cap | 1.70B |
Pliant Therapeutics Inc. (PLRX) Company Bio
Pliant Therapeutics, Inc. engages in the business of developing and commercializing novel therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. Pliant Therapeutics was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Latest PLRX News From Around the Web
Below are the latest news stories about PLIANT THERAPEUTICS INC that investors may wish to consider to help them evaluate PLRX as an investment opportunity.
Pliant Therapeutics prices $250M upsized offering
|
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's WhyShares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients. |
Pliant Therapeutics Announces Appointment of Lily Cheung as Chief Human Resources OfficerSOUTH SAN FRANCISCO, Calif., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced Ms. Lily Cheung as its Chief Human Resources Officer. Ms. Cheung brings over 25 years of Human Resources experience across the technology and biopharmaceutical industries, including more than 15 years of commercial-stage experience. Ms. Cheung joins Pl |
Pliant Therapeutics Announces Pricing of Upsized $250.0 Million Public OfferingSOUTH SAN FRANCISCO, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced the pricing of an upsized underwritten public offering of 8,333,334 shares of its common stock at a price to the public of $30.00 per share. The aggregate gross proceeds from the offering are expected to be approximately $250.0 million, before deductin |
Dow, Nasdaq Boasting Triple-Digit Midday LeadInvestors seem intent on leaving last week's losses behind, as earnings season heats up. |
PLRX Price Returns
| 1-mo | 86.17% |
| 3-mo | 39.37% |
| 6-mo | 111.33% |
| 1-year | 202.95% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 80.39% |
| 2022 | 43.19% |
| 2021 | -40.58% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...